Minocycline is used as a disease-modifying anti-rheumatic drug (DMARD) for its ability to treat connective tissue manifestations, such as calcinosis cutis and bullous phemhigoid, in addition to its bacteriostatic antimicrobial effects.
Calcinosis cutis in autoimmune connective tissue diseases. Dermatol Ther. 2012 Mar-Apr;25(2):195-206. doi: 10.1111/j.1529-8019.2012.01492.x.
Article abstract in Dermatology and Therapy describing the use of minocycline and various other treatments for calcinosis cutis, commonly suffered in connective tissue diseases, such as systemic scleroderma and dermatomyositis .
Calcinosis in rheumatic diseases. Semin Arthritis Rheum. 2005 Jun;34(6):805-12.
A MEDLINE search of articles between 1972-2004, published in Seminars in Arthritis and Rheumatism, mentioning minocycline among currently available treatments, but also describing deficiencies in an organized approach to calcinosis treatment due to a lack of a generally accepted classification, systemic studies and clinical therapeutic trials.
[Treatment of subcutaneous calcinosis in systemic disorders]. Rev Med Interne. 2014 Jul;35(7):444-52. doi: 10.1016/j.revmed.2014.04.018. Epub 2014 May 28.
Article abstract in La Revue de Medédine Interne outlining treatments that include the systemic use of minocycline for calcinosis cutis, a common metabolic disturbance of calcium and/or phosphate metabolism in connective tissue diseases, such as limited scleroderma and dermatomyositis.
Bullous pemphigoid associated with dermatomyositis successfully controlled with minocycline. Clin Exp Dermatol. 2003 Sep;28(5):563-4.
Case study abstract unavailable, but may be available by subscribing to the journal in which it is published.